Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financing

Set Alert for Financing

In Investing, Oncology Is Still King, But Other Indications Joining The Royal Court

Investing in oncology has diminished as more focus goes to clinical-stage firms, while investment in preclinical companies in areas like neurology has been heating up.

Deals Financing

Finance Watch: Denali, Avidity And Others Chase Big Money Via Private Placements

Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.

Financing Business Strategies

Optimistic IPO Outlook For Biopharma Fueled By Early Trends

The US market for biopharma initial public offerings is expected to return to a more normal level in 2024, according to experts at the BIO CEO & Investor Conference.

Financing Business Strategies

Finance Watch: Frontier Raises $80m For Differentiated KRAS G12C Program

Private Company Edition: With its lead program in the clinic, Frontier’s $80m series C round will fund trials for additional programs. Also, ORI raises $260m for second fund, Earlybird closed a €173m ($187.1m) fund, Areteia’s series A grew to $425m and Sudo’s series B increased to $147m.

Financing Innovation

IsomAb Nabs Decent Seed Funding Despite Tricky Funding Climate

The University of Nottingham spin-out has raised £7.5m for a candidate that could halt the progression of peripheral arterial disease in diabetics.

Financing Cardiovascular

Finance Watch: Merrimack And LianBio Are Latest To Liquidate As Options Run Out

Restructuring Edition: The financial market is beginning to perk up after a decline in biopharma financings at the end of 2023, but some companies still are struggling to stay afloat after assessing their strategic options, like Merrimack and LianBio, which announced plans to dissolve.

Financing Restructuring

Aurinia Make Cuts After Fruitless Search For Buyer

The company will now focus on maximizing uptake of its lupus nephritis treatment Lupkynis.

Companies Financing

Finance Watch: Biopharma Public Offerings Fell In Q4, But Activity Is Booming In Q1

Public Company Edition: Fourth quarter 2023 fundraising fell 25.1% from Q4 2022, including a 24.2% drop in follow-on dollars, but recent activity has been robust, including $300m and $350m offerings by 4DMT and Autolus. Also, BMS sold $13bn in notes to fund Karuna and RayzeBio deals.

Financing Business Strategies

Latigo Raises $135m To Channel Vertex

The start-up is aiming to develop a NaV1.8 inhibitor for pain, but previous efforts here have met with more failure than success.

Commercial Companies

BioAge Puts VC Muscle Behind Phase II Azelaprag Trials In Obesity

The company completed a $170m series D round and plans to start trials combining the drug with GLP-1 agonists like Eli Lilly’s Zepbound in mid-2024.

Financing StartUps and SMEs

Alys Puts Skin In The Dermatology Game With $100m Launch

Having adopted a similar model to set up Centessa, investment firm Medicxi is merging six of its portfolio companies to create an ambitious immuno-dermatology group.

Dermatology Financing

IPO Gives Kyverna Cash To Maintain Lead In Autoimmune CAR-T Development

Kyverna CEO Peter Maag spoke with Scrip about the company’s five-year overnight success after its well-received IPO. Metagenomi and Telomir also went public in the US in smaller offerings.

Financing Strategy
See All
UsernamePublicRestriction

Register